Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) is a publicly traded Healthcare sector company. As of May 21, 2026, RYTM trades at $90.54 with a market cap of $5.95B and a P/E ratio of -28.53. RYTM moved +3.78% today. Year to date, RYTM is -11.02%; over the trailing twelve months it is +41.91%. Its 52-week range spans $45.91 to $122.20. Analyst consensus is strong buy with an average price target of $137.64. Rallies surfaces RYTM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rhythm Pharmaceuticals jumps after Q1 revenue beat and new IMCIVREE obesity approvals: Rhythm Pharmaceuticals shares rose after the company reported Q1 2026 results on May 5, 2026, with IMCIVREE net product revenue of $60.1 million and 150 patient starts. The update also highlighted recently expanded approvals for acquired hypothalamic obesity in the U.S. (FDA approval March 19, 2026) and Europe (European Commission authorization May 1, 2026).
| Metric | Value |
|---|---|
| Price | $90.54 |
| Market Cap | $5.95B |
| P/E Ratio | -28.53 |
| EPS | $-3.13 |
| Dividend Yield | 0.00% |
| 52-Week High | $122.20 |
| 52-Week Low | $45.91 |
| Volume | 615 |
| Avg Volume | 0 |
| Revenue (TTM) | $217.16M |
| Net Income | $-202.68M |
| Gross Margin | 89.41% |
14 analysts cover RYTM: 0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $137.64.